We are investing in evidence-based medicine to improve outcomes

Since 1970, Varian has been investing in the science behind our products. With more than 300 active and approved comprehensive research collaborations and clinical trials, we are generating evidence across radiotherapy modalities such as proton therapy, proton FLASH therapy, adaptive radiotherapy, and cardiac radioablation; interventional modalities including embolization; and advanced imaging systems plus AI-powered support tools. Our goal is to empower clinicians to be more precise and make more informed decisions, enabling them to deliver the right care at the right time, fighting for a world without fear of cancer.

Working together to improve survivor outcomes in cancer care

Trends driving increased survivorship

  • Earlier diagnosis
  • New technologies / advancements
  • Patient awareness
  • Screening and Dx

5-year overall survival

*Forecasted survival rate based on increases in treatment efficacy (Phase 213 data) and liquid biopsy availability. Artificial lungs. livers. and pancreas are under development but are not expected to be commercialized by 2027.

Sources: Survival Data: (1) National Cancer Institute’s SEER*Stat 8.3.4 databases, (2) Genomic Health Clinical Validation Trials, (3) Roche IMpassion 130 trial, additional on file.

Investing in evidence-based medicine

Evidence generation to drive advances in standard of care

Adaptive radiotherapy

Ongoing Ethos trials focusing on different disease sites and clinical scenarios

  • 16 disease sites
  • 1000+ planned participants
  • 30+ trials

Advanced imaging

Ongoing & committed trials HyperSight on Halcyon/Ethos HyperSight on TrueBeam

  • 8 trials
  • 200+ planned participants
  • 7 institutions

Cardiac radioablation

Multi-institutional, multi-national randomized controlled clinical trial

  • 380 planned participants
  • 20 institutions

Interventional radiology

Ongoing & committed clinical trials

  • 6 trials
  • 650+ planned participants

Proton Flash therapy

Ongoing & committed clinical trials

  • 10 participants treated FAST 01
  • 10 participants planned FAST 01

FAST-01 results in JAMA Oncology FAST-01 trial cited by Physics World’s as a Top 10 Breakthrough of 2022

Evidence that Demonstrates Value

Working collaboratively with cancer care teams, institutions, and societies across the globe, we help contribute to the body of knowledge about cancer treatment technologies and advancements across many treatment areas.

Adaptive Radiotherapy

Ongoing increase in adaptive publications

Since 1997, over 1600 peer-reviewed publications using adaptive radiotherapy have appeared in various clinical journals, and the number is growing. They include: randomized studies, systematic reviews, real world evidence analysis, prospective and retrospective comparison studies, pre-clinical studies.

  • Multi-institutional, multi-national Ethos clinical trials across disease sites and clinical scenarios: See the studies
  • Investigator-led adaptive studies: See the studies

Resources